INBUILD
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Patient / Population Intervention / Exposition Comparaison Critère de jugement
In 663 patients with non-IPF progressive fibrosing ILD, nintedanib slowed annual FVC decline compared with placebo.
N
663
Schéma
Multicentre RCT
Critère
Annual rate of FVC decline
Pertinence
2
Résultat-80.8 vs -187.8 mL/year (difference 107 mL; p<0.001); effect consistent across UIP and non-UIP HRCT pattern.
Flaherty KR, et al. N Engl J Med. 2019;381(18):1718-1727. 10.1056/NEJMoa1908681
Discussion et critique
Broadened nintedanib's indication beyond IPF to any progressive fibrosing ILD.